A phase I/II trial of intensity modulated radiation (IMRT) dose escalation with concurrent fixed-dose rate gemcitabine (FDR-G) in patients with unresectable pancreatic cancer.
about
Recent progress in pancreatic cancerManagement of borderline resectable pancreatic cancerAdvances of stereotactic body radiotherapy in pancreatic cancerEffect of cytotoxic chemotherapy on markers of molecular age in patients with breast cancer.Accelerated fraction radiotherapy with capecitabine as neoadjuvant therapy for borderline resectable pancreatic cancer.Radiation dose ≥54 Gy and CA 19-9 response are associated with improved survival for unresectable, non-metastatic pancreatic cancer treated with chemoradiation.A multi-institutional phase 2 study of neoadjuvant gemcitabine and oxaliplatin with radiation therapy in patients with pancreatic cancer.A phase I/II study of fixed-dose-rate gemcitabine and S-1 with concurrent radiotherapy for locally advanced pancreatic cancer.Neoadjuvant Gemcitabine Chemotherapy followed by Concurrent IMRT Simultaneous Boost Achieves High R0 Resection in Borderline Resectable Pancreatic Cancer Patients.Challenges in using ¹⁸F-fluorodeoxyglucose-PET-CT to define a biological radiotherapy boost volume in locally advanced pancreatic cancerAdaptive dose-finding studies: a review of model-guided phase I clinical trials.Radiosensitization of Pancreatic Cancer Cells In Vitro and In Vivo through Poly (ADP-ribose) Polymerase Inhibition with ABT-888.Combined inhibition of Wee1 and PARP1/2 for radiosensitization in pancreatic cancer.Inhibition of protein phosphatase 2A radiosensitizes pancreatic cancers by modulating CDC25C/CDK1 and homologous recombination repairPhase 2 study of erlotinib combined with adjuvant chemoradiation and chemotherapy in patients with resectable pancreatic cancer.Targeting mcl-1 for radiosensitization of pancreatic cancers.Phase 2 multi-institutional trial evaluating gemcitabine and stereotactic body radiotherapy for patients with locally advanced unresectable pancreatic adenocarcinomaSelective radiosensitization of p53 mutant pancreatic cancer cells by combined inhibition of Chk1 and PARP1.Adjuvant radiation therapy for pancreatic cancer: a review of the old and the new.Robotic radiosurgery in pancreatic cancer: A systematic review.Pancreatic cancer and SBRT: A new potential option?Sensitization of Pancreatic Cancers to Gemcitabine Chemoradiation by WEE1 Kinase Inhibition Depends on Homologous Recombination RepairModelling duodenum radiotherapy toxicity using cohort dose-volume-histogram dataGemcitabine Plus Radiation Therapy for High-Grade Glioma: Long-Term Results of a Phase 1 Dose-Escalation Study.Focal Radiation Therapy Dose Escalation Improves Overall Survival in Locally Advanced Pancreatic Cancer Patients Receiving Induction Chemotherapy and Consolidative Chemoradiation.Gemcitabine-based or capecitabine-based chemoradiotherapy for locally advanced pancreatic cancer (SCALOP): a multicentre, randomised, phase 2 trial.CA19-9 Normalization During Pre-operative Treatment Predicts Longer Survival for Patients with Locally Progressed Pancreatic CancerSensitization of pancreatic cancer to chemoradiation by the Chk1 inhibitor MK8776Phase II Trial of Cetuximab and Conformal Radiotherapy Only in Locally Advanced Pancreatic Cancer with Concurrent Tissue Sampling Feasibility Study.The influence of radiation therapy dose escalation on overall survival in unresectable pancreatic adenocarcinoma.Proton therapy with concomitant capecitabine for pancreatic and ampullary cancers is associated with a low incidence of gastrointestinal toxicity.Management options in locally advanced pancreatic cancer.Glycogen Synthase Kinase 3β in Pancreatic Cancer and its Implications in Chemotherapy and Radiation Therapy.Stereotactic body radiation therapy in pancreatic cancer: the new frontier.Dose-painted intensity modulated radiation therapy improves local control for locally advanced pancreas cancer.Multiagent induction chemotherapy followed by chemoradiation is associated with improved survival in locally advanced pancreatic cancer.Particle Radiation Therapy for Gastrointestinal Cancers.Stereotactic body radiotherapy for renal cell cancer and pancreatic cancer : Literature review and practice recommendations of the DEGRO Working Group on Stereotactic Radiotherapy.A dosimetric comparison of proton and photon therapy in unresectable cancers of the head of pancreas.Chemotherapy and intensity-modulated radiation therapy for locally advanced pancreatic cancer achieves a high rate of R0 resection.
P2860
Q24626346-BDDE08FD-54F1-44BB-925C-1820AE9CE02CQ26781445-8F779811-1ADE-41D3-9ED3-489FE88BBCDFQ26781550-926F991D-9943-4FD4-ADB6-D6FEA2D44856Q30406114-BB87F3F7-5D9B-4862-83B0-BCFD4A26A4C0Q30414737-BCD9D669-EFF8-45CD-9F0B-1B77AEDD2747Q30423279-E3C32EFB-FD39-432F-80EF-80531ED78DB1Q33408075-4F1B3282-88EC-4D2C-807C-90BE3E2F5161Q33424803-F9DDE545-3711-4079-9AAA-E88C85C3348EQ33437515-A73C04D3-9068-4D38-8349-CC75751D1DF3Q33833200-1B87C26A-FDE0-4F9E-9781-175D632C76AAQ34001009-01AC8832-F3EB-41D3-B07A-8242C3F2901CQ34092001-DFCC6386-03E2-4F0D-A4CA-1A560436C084Q34287982-E5A202C0-26C2-4629-A563-9C8A69FBB859Q34777845-26D98011-0307-43BB-AD65-1C553B45DFD5Q35067737-174A9B49-A347-4315-9039-6E8E1B971718Q35150651-BC882146-24B5-43BD-8C18-BA40073B23E0Q35202400-D1B7D0F5-F869-415E-BB4F-DD7FFFF6B48EQ35737519-83A4EA80-CDC0-4D47-BC48-276F2FC03524Q35851281-BCFBA10D-4EC1-4ACC-BAF2-937DB21E80FCQ35970200-DD90E17E-5B3C-46F4-8DAB-5F67D58A2746Q36133787-2235F388-1CB6-4861-9B5C-78ABE73EA98EQ36309585-B36E5726-35BA-4A19-BCB0-20302D74EAC6Q36397239-8DF4DBCE-E69B-4FCF-85F3-AB7E92224567Q36559617-789933F4-566F-4376-91DE-2004705816C4Q36688010-51E45496-B00A-4A99-A231-41DB626592F5Q36751555-B61FB66E-285A-4754-A196-E7C232DB811EQ37033444-69AE9409-2481-4FB8-9D53-40E35E0D6AEFQ37100166-464D0020-D8D5-43B8-950F-AF572D59C80CQ37721562-5274EB41-6A57-45D5-B81A-FD2C75BE6167Q37723257-C415C046-40DA-4437-BDDC-DD73FB1461F0Q38087989-A93F9B77-AA50-41FC-B641-D35EF8821E1BQ38205127-CC93567D-70D3-489B-94D0-99DDF7895DA4Q38221504-8B7E5FD3-69A6-48D9-8FAE-D7E5827D194CQ38245676-46D79EE8-9413-4EB5-94EE-E9B69DDD4E4EQ38429492-70258DF3-DAC7-40D7-887E-63C95C31F3CAQ38722475-72407278-8CE3-4B79-943E-A3FCDD411007Q38724284-83F20207-D724-43DD-BAE9-69281C711060Q38806110-6380D5BA-FFF5-4197-ADF5-BCBDB9F6E33EQ39149609-9DD23E7A-255A-477C-AF3A-BCA044BFB122Q39234276-88E7ACF5-AEF4-4A5A-B947-FE3EBFAEC0CB
P2860
A phase I/II trial of intensity modulated radiation (IMRT) dose escalation with concurrent fixed-dose rate gemcitabine (FDR-G) in patients with unresectable pancreatic cancer.
description
2012 nî lūn-bûn
@nan
2012 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
A phase I/II trial of intensit ...... nresectable pancreatic cancer.
@ast
A phase I/II trial of intensit ...... nresectable pancreatic cancer.
@en
type
label
A phase I/II trial of intensit ...... nresectable pancreatic cancer.
@ast
A phase I/II trial of intensit ...... nresectable pancreatic cancer.
@en
prefLabel
A phase I/II trial of intensit ...... nresectable pancreatic cancer.
@ast
A phase I/II trial of intensit ...... nresectable pancreatic cancer.
@en
P2093
P2860
P1476
A phase I/II trial of intensit ...... nresectable pancreatic cancer.
@en
P2093
Christopher Sonnenday
Diane M Simeone
Gazala Khan
Isaac R Francis
Mark M Zalupski
Mathew Schipper
Randall Ten-Haken
Ross Abrams
Scott Hadley
Theodore Lawrence
P2860
P304
P356
10.1016/J.IJROBP.2012.02.051
P407
P577
2012-04-27T00:00:00Z